Prostate cancer is the most common cancer among men in the United States and the second most common malignant cause of male deaths in the United States. There is currently no effective therapy for late-stage disease, whereas surgery or radiation therapy is the only choice for early-stage disease. Immunotherapy affords a promising approach to the treatment of various types of cancer, including prostate cancer (1 -5). Although peptide-or dendritic cell -based vaccines can induce antigenspecific immune responses, objective clinical responses remain infrequent and transient (3, 6) . A possible explanation is that tumor cells may create an immunosuppressive environment in cancer patients. Thus, a better understanding of the interaction between tumor-infiltrating immune cells and cancer cells is critical to efforts to devise strategies that would enhance the therapeutic efficacy of immunologic interventions.
Experimental Design: Tumor-infiltrating lymphocytes (TIL) from fresh tumor specimens of patients with prostate cancer were generated and subjected to phenotypic and suppressive function analyses. In particular, we investigated the role and function CD8 + Treg cells in prostate cancer. Results: We show that high percentages of CD4 + CD25 + T cells are probably present in the majority (70%) of prostate TILs. Remarkably, both CD4 + and CD8 + T-cell subpopulations possessed potent suppressive activity. T-cell cloning and fluorescence-activated cell sorting analyses showed the presence of CD8 + CD25 + Treg cell clones that expressed FoxP3 and suppressed naI« ve T-cell proliferation, in addition to the previously known CD4 + CD25 + Treg cells. These CD8 + Treg cells suppressed naI« ve T-cell proliferation mainly through a cell contactd ependent mechanism. Importantly, the suppressive function of CD8 + Treg cells could be reversed by humanToll-like receptor 8 (TLR8) signaling. Conclusion: Our study shows that like CD4 + CD25 + Treg cells, CD8 + Foxp3 + Treg cells present in prostate tumor^derived TILs suppress immune responses and that their suppressive function can be regulated by TLR8 ligands, raising the possibility that the manipulation of Treg cell function by TLR8 ligands could improve the efficacy of immunotherapy for prostate cancer patients.
Prostate cancer is the most common cancer among men in the United States and the second most common malignant cause of male deaths in the United States. There is currently no effective therapy for late-stage disease, whereas surgery or radiation therapy is the only choice for early-stage disease. Immunotherapy affords a promising approach to the treatment of various types of cancer, including prostate cancer (1 -5) . Although peptide-or dendritic cell -based vaccines can induce antigenspecific immune responses, objective clinical responses remain infrequent and transient (3, 6) . A possible explanation is that tumor cells may create an immunosuppressive environment in cancer patients. Thus, a better understanding of the interaction between tumor-infiltrating immune cells and cancer cells is critical to efforts to devise strategies that would enhance the therapeutic efficacy of immunologic interventions.
Recent studies indicate that preexisting CD4 + regulatory T (Treg) cells at tumor sites may pose major obstacles to effective cancer immunotherapy, as these cells have a potent ability to suppress host immune responses (7 -9) . Indeed, increased proportions of CD4 + CD25 + Treg cells in the total CD4 + T-cell populations have been documented in patients with different types of cancers, including lung, breast, and ovarian tumors (10 -12) . Our recent findings further show the presence of antigen-specific CD4 + Treg cells at tumor sites, where they induce antigen-specific and local immune tolerance (7, 8) . The removal or elimination of Treg cell populations with anti-CD25 monoclonal antibody (mAb) treatment results in effective rejection of transplanted tumors in animal models (13) , further suggesting a functional role for these Treg cells in tumor progression and immunosuppression.
Because Treg cell -mediated immunosuppression exists at tumor sites, a new strategy for depletion of Treg cells or reversal of the suppressive function of Treg cells will be important in efforts to induce antigen-specific effector T cells. Thus, we recently showed that Toll-like receptor 8 (TLR8) ligands can specifically reverse the suppressive function of both antigen-specific and naturally occurring Treg cells (14) 
Materials and Methods
Generation of tumor-infiltrating T cells and T-cell cloning. Prostate cancer tissues or melanoma samples were minced into small pieces followed by digestion with triple-enzyme mixture containing collagenase type IV, hyaluronidase, and DNase for 2 h at room temperature. After digestion, the cells were washed twice in RPMI 1640 and cultured in RPMI 1640 containing 10% human serum supplemented with L-glutamine and 2-mercaptethanol and 1,000 U/mL of IL-2 for the generation of T cells over 2 to 3 weeks. Experiments for human materials and tumor sample collection is conducted under the institutional review board protocol (H-9086) approved by Baylor College of Medicine Institutional Review Board committee. T-cell clones were generated from TILs by the limiting dilution cloning method, as previously reported (7) . T-cell clones were transferred to fresh 96-well plates and used in a functional assay to determine their ability to inhibit naBve T-cell proliferation. Some T-cell clones with suppressive activity were selected for further analyses. 1359 1E3 T cells generated from melanoma TIL 1359 suppressed naBve T-cell proliferation and served as a control for CD4 + Treg cells. Fluorescence-activated cell sorting analysis of CD25 and GITR. CD4 + and CD8 + T-cell populations were purified with specific antibodycoated beads. The expression of CD25 and GITR on Treg cells was determined by fluorescence-activated cell sorting (FACS) analysis after staining with specific antibodies (purchased from R&D Systems and BD Biosciences), as previously described (7, 8) . 3 ]thymidine for the last 16 h of culture, as previously described (7, 8) . Cells were harvested, and the radioactivity was counted in a scintillation counter. All experiments were done in triplicate. Transwell experiments were done in 24-well plates with a pore size of 0.4 Am (Corning Costar).
PCR analysis of FoxP3 and TLR8. Total RNA was extracted from 1 Â 10 7 T cells using TRIzol reagent (Invitrogen, Inc.). A SuperScript II reverse transcription kit (Invitrogen) was used to perform reverse transcription, in which 20 AL of the reverse transcription mixture, containing 2 Ag of total RNA, were incubated at 42jC for 1 h. FoxP3 mRNA levels were quantified by real-time PCR using ABI/PRISM7000 sequence detection system (PE Applied Biosystems, Inc.). The PCR reaction was done with primers and an internal fluorescent TaqMan probe specific for FoxP3 or HPRT, all purchased from PE Applied Biosystems. FoxP3 mRNA levels in each sample were normalized with the relative quantity of HPRT. All samples were run in triplicate. For analysis of TLR8, we did PCR analysis with the TLR8 forward primer, 5 ¶-TTTCCCACC-TACCCTCTGGCTT-3 ¶, and the reverse primer, 5 ¶-TGCTCTGCATGAGG TTGTCGGATGA-3 ¶. The primers for reverse transcription-PCR of Foxp3 were Foxp3-5P, 5 ¶-GCCCTTGGACAAGGACCCGATG-3 ¶ and Foxp3-3P, 5 ¶-CATTTGCCAGCAGTGGGTAGGAG-3 ¶. PCR amplification for glyceraldehyde 3-phosphate dehydrogenase served as a PCR control (forward primer, 5 ¶-CGAGATCCCTCCAAAATCAA-3 ¶; reverse primer, 5 ¶-TGTGGT-CATGAGTCCTTCCA-3 ¶).
Immunohistochemical staining of tumor tissues. Prostate cancer tissues and normal prostate tissues were stained with mouse antihuman CD8 (1:10 dilution, BD PharMingen) and goat anti-human Foxp3 IgG (1:100 dilution, Novus Biologicals), followed by Alexa Fluor 633 -conjugated goat anti-mouse IgG and Alexa Fluor 488 donkey antigoat IgG (2 Ag/mL; Molecular Probes). Immune staining -positive cells were detected with a fluorescence confocal microscopy.
Toll-like receptor ligands and proliferation assays. NaBve CD4 + T cells were purified from PBMCs by use of microbeads (Miltenyi Biotec). NaBve CD4 + T cells (10 5 /well) were cultured with Treg cells at a ratio of 10:1 in OKT3 (2 Ag/mL) -coated, U-bottomed 96-well plates containing the following ligands. Lipopolysaccharide (100 ng/mL), imiquimod (10 Ag/mL), loxoribine (500 Amol/L), copolymer of polyinosinic and polycytidylic acids (25 Ag/mL), ssRNA40/LyoVec (3 Ag/mL), ssRNA33/ LyoVec (3 Ag/mL), pam3CSK4 (200 ng/mL), and flagellin (10 Ag/mL) were all purchased from Invivogen. CpG-A (3 Ag/mL), CpG-B (3 Ag/mL), and poly-G oligonucleotides (3 Ag/mL) were synthesized by Integrated DNA Technologies. + T cells in the total T-cell population, and did not produce a suppressive effect on naBve T-cell proliferation, while the remaining 16 TILs (72%), including PTIL157, PTIL194, PTIL237, and PTIL313, contained elevated percentages (11-77%) of CD4 + CD25 + T cells in the total T-cell population, and showed a potent ability to suppress naBve T-cell proliferation. Representative data are shown in Fig. 1A + T cells, did not have a suppressive effect on naBve T-cell proliferation (Fig. 1C) . The mean + T cells in melanoma-derived TILs was significantly lower than that in prostate tumor -derived TILs (Fig. 1D ). These results suggest that the majority of prostate cancer -derived TILs, but only a small percentage of melanomaderived TILs, contained elevated proportion of CD4 + CD25 + T cells and exhibited suppressive activity, which may explain why melanoma-derived T cells are relatively easy to grow and expand in vitro.
Results

Treg
Suppression of naBve T-cell proliferation by CD4 + and CD8 + subsets of Treg cells. To determine the subsets of Treg cells responsible for the observed suppression of naBve T-cell proliferation, we selected four bulk TIL cell lines (PTIL157, PTIL194, PTIL237, and PTIL313) for further analysis. CD4 + and CD8 + T-cell subpopulations were purified from bulk T-cell lines with anti-CD4 or anti-CD8 antibody -coated magnetic beads and tested for their ability to inhibit the proliferation of naBve CD4 + T cells. As expected, CD4 + T-cell population showed a marked suppressive effect; however, we also found that CD8 + T populations isolated from four TILs were suppressive, suggesting that the purified CD8 + T-cell population contained CD8 + Treg cells ( Fig. 2A) 
Generation of CD8 + Treg cell clones with suppressive function. To show the presence of CD8 + Treg cells in prostate cancer -derived TILs, we established T-cell clones from PTIL194 by limiting dilution cloning. More than 100 T-cell clones were obtained and analyzed for their ability to inhibit naBve T-cell proliferation in a functional assay. A representative set of data is shown in Fig. 4A . Among 94 T-cell clones, 51 had strong suppressive activity, whereas 43 had little or no suppressive activity. These results are consistent with data in Fig. 3C showing both Foxp3 + and Foxp3 -T cells present in prostate tissues. To determine the cell phenotype of clones with suppressive activity, we did FACS analysis. As expected, some of T-cell clones with a suppressive function were CD4 + T cells that expressed CD25, GITR, CD122 (IL-2 receptor h chain), and Foxp3 molecules, whereas the remaining clones were the suppressive CD8 + T cells that expressed CD25, CD122, and Foxp3, but were negative for GITR. Representative data for both CD4 + and CD8 + Treg cells (two for each cell type) are shown in Fig. 4B . Nonsuppressive CD4 + or CD8 + T cells were negative for CD25 and Foxp3 molecules (data not shown). It has been reported that CCR4 is expressed in Treg cells (11 + and CD8 + T-cell populations from PTIL194 and PTIL237 inhibited naBve CD4 T-cell proliferation in the coculture assay condition, T cells from PTIL237 could not suppress naBve CD4 T-cell proliferation in a transwell system (Fig. 5A ), suggesting that cell-to-cell contact is required for immunosuppression by PTIL237. Similarly, we found that like CD4 + Treg cells, PTIL237-derived CD8 + Treg cell clones suppressed naBve T-cell proliferation in a cell contactdependent manner (data not shown). However, T cells from PTIL194 showed partial inhibition of naBve T cells in a transwell system (Fig. 5A) , indicating that some Treg cells in PTIL194 inhibit naBve T-cell proliferation through a cell contactdependent mechanism, whereas others suppress immune responses via soluble factors (IL-10 and/or transforming growth factor-h). Indeed, we found that some Treg cell clones from PTIL194 could not inhibit naBve CD4 T-cell proliferation in a HD2) and prostate cancer patients (PP1 and PP2). PBMCs were obtained from healthy donors and prostate cancer patients and stained with anti-Foxp3, anti-CD8, and anti-CD4 antibodies. Similar results were obtained with additional PBMCs (five healthy donors and five prostate cancer patients). C, immunohistochemical staining for CD8 and Foxp3 expression in prostate tumor tissues. Frozen prostate tumor tissues were stained with anti-CD8 (red) and anti-Foxp3 (green) and detected with a confocal microscope. Fluorescence images were merged. Arrows, cells express both CD8 (red) and Foxp3 (green) molecules to generate yellow fluorescence. Similar results were obtained with two repeated experiments and three different prostate tumor tissues. transwell assay, whereas others could partially inhibit naBve T-cell proliferation in a transwell system (Fig. 5B) . However, the addition of anti -IL10, anti -transforming growth factor-h, or both antibodies could not restore naBve T-cell proliferation (data not shown). It has been shown that murine CD8 + suppressor T cells suppress immune response through interaction between Qa-1 and CD94 molecules (16) . To exclude the possibility that human HLA-E or CD94 molecules are involved in CD8 + Treg cell -mediated immunosuppression, we did a functional assay in the presence of anti-CD94 or control antibody and found that neither anti-CD94 nor control antibody affected the suppressive function of CD8 + Treg cells (Fig. 5C ). These results suggest that like CD4 + Treg cells, CD8 + Treg cells suppressed immune responses through both soluble factordependent and cell contact -dependent suppressive mechanisms, which are distinct from murine Qa-1 -restricted CD8 + suppressor cells.
Reversal of CD8 + Treg cell function by TLR8 ligands. We recently showed that the suppressive function of CD4 + Treg cells can be reversed by TLR ligands (14) ; however, it was not clear whether activation of TLR8 signaling can also reverse the suppressive function of CD8 + CD25 + Treg cells. To test this possibility, we purified CD8 + Treg cells from PTIL194 and tested for their suppressive effect on naBve T-cell proliferation in the presence and absence of TLR8 ligands (poly-G2 and ssRNA40) or ligands for other TLRs. We found that the suppressive activity of CD8 + Treg cell population was abolished by TLR8 ligand poly-G2 and ssRNA40 but was not affected by ligands for other TLRs (Fig. 6A) . Figure 6B is + Treg cell clones responded to poly-G2 treatment. Treatment of poly-G2 oligonucleotides completely restored naBve T-cell proliferation (Fig. 6C) , suggesting that TLR8 signaling controls the suppressive function of CD8 + Treg cells. Consistent with this observation, we found that TLR8 expression could be detected in CD8 + Treg cell clones, CD4 + Treg cell clones, and PBMCs, whereas fibroblasts did not express TLR8 (Fig. 6D) . Thus, besides their similarities in phenotypic and suppressive mechanisms between CD4 + and CD8 + Treg cells, they also share a common pathway for their functional regulation through the TLR8 signaling. These results raise a possibility that manipulation of TLR8 signaling pathway can 
Discussion
Increasing evidence indicates that tumor-infiltrating immune cells play a major role in combating cancer and their activity correlates with disease prognosis and survival (17, 18) . In most cases, however, tumor-specific T cells ultimately fail to control tumor growth. However, the clinical response rate could be improved to 50% if patients scheduled to receive adoptive T-cell therapy were first conditioned with cyclophosphamide for 2 days to remove whole-body lymphocytes (19). These results suggest that tumor-specific T cells may be suppressed by Treg cells in the tumor microenvironment, and their removal by cyclophosphamide may enhance antitumor immunity.
Although elevated proportions of Treg cells have been reported in patients with other cancers (10, 11), relatively less is known about Treg cells in prostate cancer. Analysis of the prevalence of different Treg cell subpopulations as well as their suppressive mechanisms in prostate cancer patients are critical to our understanding immunosuppression in prostate cancer and to devising new strategies for improving the efficacy of cancer vaccines. Several lines of evidence suggest that prostatederived TILs are distinct from those derived from other types of cancers. First, we found that the majority of prostate tumorderived TILs contained high percentages of CD4 + CD25 + Treg cells (Fig. 1) . Further experiments show, however, that the frequency of CD4 + Foxp3 + and CD8 + Foxp3 + T cells in normal PBMCs is comparable with that in PBMCs of cancer patients (Fig. 3) + Treg cells inhibit naBve T-cell proliferation through a cell contact -dependent as well as soluble factor -dependent mechanisms, but do not require the involvement of Qa-1 and CD94 interaction, which is critical for murine CD8 + suppressor T cells (16, 23 (36 -38) . Prostate cancer is concomitantly associated with prostatitis or inflammation that may create a specific cytokine environment favoring the expansion of Treg cells (39, 40) . Suppressive cytokines such as IL-10 and transforming growth factor-h and chemokines such as CCL22 secreted by tumor cells or tumor-infiltrating macrophages, myeloid suppressor cells, and dendritic cells not only recruit Treg cells to tumor sites but also favor the conversion of nonsuppressive T cells into Treg cells with suppressive function (11, 41) . This notion is supported by our findings showing that prostate tumor -derived CD4 + CD25 + Treg cells express CCR4, a receptor for CCL22. However, CD8 + CD25 + Treg cells do not express CCR4 molecules. Second, it is likely that tumor cells may actively recruit, activate, and expand Treg cells by either directly or indirectly presenting antigenic peptides for their recognition. Indeed, our previous studies showed that tumor cells express tumor-specific antigens such as LAGE1 and ARTC1 and directly stimulate antigen-specific Treg cells (7, 8) . Because some prostate tumor -derived TILs had tumor-specific recognition (data not shown), it is reasonable to believe that tumor antigens expressed by prostate tumor cells may play a critical role in the recruitment, activation, and maintenance of Treg cells at tumor sites. Thus, antigens expressed by tumor cells, soluble factors, and cytokines/chemokines in tumor microenvironments may play a critical role in recruiting, expanding, and maintaining Treg cells at tumor sites (42 
